Targeted Pulse Quiz: October 13

Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.

The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.

ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.

VIR-5500 and [²¹²Pb]PSV359 received FDA fast track designations for prostate cancer and solitary fibrous tumors, respectively.

The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.

Pan-cancer study shows age-based germline testing misses most inherited cancer variants, supporting broader genetic screening to guide treatment and family risk.